| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.05. | DIAMYD MEDICAL AB: Diamyd Medical updates on the registrational Phase 3 trial; upcoming interim analysis and enrollment | 3 | Cision News | ||
| 18.04. | DIAMYD MEDICAL AB: Diamyd Medical announces final outcome in the company's rights issue | 2 | Cision News | ||
| 16.04. | DIAMYD MEDICAL AB: Diamyd Medical announces preliminary outcome in the company's rights issue | 1 | Cision News | ||
| 12.04. | Diamyd Medical AB: Recruitment milestone reached in Diamyd® Phase 3 trial | 328 | PR Newswire | STOCKHOLM, April 12, 2024 /PRNewswire/ -- Diamyd Medical's precision medicine Phase 3 trial for Type 1 Diabetes, DIAGNODE-3, has enrolled 100 patients. To date, no serious adverse events... ► Artikel lesen | |
| 11.04. | DIAMYD MEDICAL AB: Diamyd Medical led ASSET innovation partnership organizes a workshop on the future treatment of Type 1 Diabetes | 1 | Cision News | ||
| 05.04. | DIAMYD MEDICAL AB: Diamyd Medical's main Shareholders announce their subscription commitments in the ongoing rights issue | 1 | Cision News | ||
| 28.03. | Nasdaq Stockholm AB: Listing of unit rights and paid subscription units of Diamyd Medical AB | 199 | GlobeNewswire | With effect from April 02, 2024, the unit rights in Diamyd Medical AB will be
traded on First North Growth Market. Trading will continue up until and
including April 11, 2024.
Instrument: Unit... ► Artikel lesen | |
| 28.03. | DIAMYD MEDICAL AB: Diamyd Medical publishes prospectus with regards to the rights issue | 2 | Cision News | ||
| 18.03. | DIAMYD MEDICAL AB: The Board of Directors in Diamyd Medical have resolved on a rights issue of approximately SEK 114 million | 1 | Cision News | ||
| 29.02. | DIAMYD MEDICAL AB: Diamyd Medical to present new genetic data at the ASIT summit in Boston, MA | 2 | Cision News | ||
| 15.02. | Diamyd Medical AB: Diamyd Medical receives U.S. FDA Fast Track designation for Diamyd® | 424 | PR Newswire | STOCKHOLM, Feb. 15, 2024 /PRNewswire/ -- Diamyd Medical announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Diamyd® (rhGAD65/alum) that... ► Artikel lesen | |
| 14.02. | DIAMYD MEDICAL AB: Publication in Diabetologia highlights AI's potential for Type 1 Diabetes screening | 2 | Cision News | ||
| 24.01. | DIAMYD MEDICAL AB: In-depth analysis of Diamyd® Phase II trial further supports value of preserved insulin secretion | 1 | Cision News | ||
| 24.01. | Diamyd Medical AB (publ): Quarterly Report I 23/24 | 79 | GlobeNewswire (Europe) | September 2023 - November 2023, Diamyd Medical AB (publ), Fiscal year 2023/2024
Precision Medicine for Autoimmune Diabetes in Pivotal Phase 3
Diamyd Medical's B-share is traded on Nasdaq First North... ► Artikel lesen | |
| 08.01. | Diamyd Medical AB: Diamyd Medical gains market research findings to guide U.S. commercial strategy | 283 | PR Newswire | STOCKHOLM, Jan. 8, 2024 /PRNewswire/ -- Market research including initial interviews with US health care practitioners as well as US payers demonstrated a strong willingness to consider prescribing... ► Artikel lesen | |
| 04.01. | DIAMYD MEDICAL AB: Diamyd® precision medicine Phase 3 trial key interim analysis in July | 1 | Cision News |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| TUI | 5.854 |
| GAMESTOP | 3.896 |
| NEL | 3.733 |
| NVIDIA | 3.720 |
| EVOTEC | 3.423 |
| BAYER | 2.614 |
| PLUG POWER | 2.203 |
| BYD | 1.949 |
| VOLKSWAGEN | 1.424 |
| DEUTSCHE LUFTHANSA | 1.322 |
| RHEINMETALL | 1.265 |
| SUPER MICRO COMPUTER | 1.191 |
| BIONTECH | 1.181 |
| DEUTSCHE TELEKOM | 1.177 |
| ALLIANZ | 1.124 |
| AIXTRON SE | 997 |
| DEUTSCHE BANK | 914 |
| SIEMENS ENERGY | 908 |
| COMMERZBANK | 864 |
| RWE | 860 |
| BASF | 845 |
| THYSSENKRUPP | 805 |
| TESLA | 783 |
| MERCEDES-BENZ | 736 |
| BARRICK GOLD | 692 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
